Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is primarily used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
## Adult Dosing
* **LGS:** The recommended starting dose is 5 mg twice daily.
* **Titration:** Dose can be increased by 5 mg to 10 mg every week, as needed and tolerated, up to a maximum of 20 mg twice daily.
* **Maintenance:** Doses are typically 10 mg to 20 mg twice daily.
## Pediatric Dosing
* **LGS (2 to less than 10 years):**
* Starting dose: 5 mg once daily.
* Titration: Increase by 2.5 mg to 5 mg every week, as needed and tolerated, up to a maximum of 10 mg twice daily.
* **LGS (10 years and older):**
* Starting dose: 5 mg twice daily.
* Titration: Increase by 5 mg to 10 mg every week, as needed and tolerated, up to a maximum of 20 mg twice daily.
*Note: Dosing in pediatric patients should be individualized and based on weight and clinical response. Some sources may recommend weight-based dosing, and specific protocols should be followed.*
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dosage adjustments are established, but lower doses may be warranted.
* **Renal Impairment:** Use with caution. No specific dosage adjustments are established, but lower doses may be warranted.
## Contraindications
* Hypersensitivity to clobazam or any component of the formulation.
* Severe respiratory impairment.
* Severe hepatic impairment.
* Myasthenia gravis.
* Severe sleep apnea.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, fatigue, aggression, irritability, upper respiratory tract infection, vomiting, ataxia, difficulty with coordination, insomnia, drooling.
* **Serious:**
* Suicidal behavior and ideation: Monitor for emergence or worsening.
* Severe cutaneous adverse reactions (SCARs): Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported. Discontinue at the first sign of rash.
* Respiratory depression: Especially when used with other CNS depressants.
* Physical and psychological dependence.
* Withdrawal symptoms upon abrupt discontinuation.
## Key Drug Interactions
* **CNS Depressants (e.g., opioids, alcohol, other benzodiazepines):** Increased risk of sedation, respiratory depression, and coma.
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, ritonavir):** May increase clobazam concentrations.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin):** May decrease clobazam concentrations.
* **Stimulants (e.g., CNS stimulants):** Monitor for paradoxical excitation.
## Monitoring
* Monitor for signs of respiratory depression, sedation, and cognitive/behavioral changes.
* Assess for suicidal behavior and ideation.
* Monitor for signs of severe cutaneous reactions.
* Evaluate for signs of tolerance and dependence, especially with long-term use.
* Monitor for withdrawal symptoms if treatment is discontinued.
## Clinical Pearls
* Clobazam has a longer half-life than many other benzodiazepines, which may allow for less frequent dosing but also increases the risk of accumulation.
* Initiate therapy with low doses and titrate slowly to minimize somnolence and other CNS adverse effects.
* Do not abruptly discontinue clobazam due to the risk of withdrawal symptoms, including seizures. Taper the dose gradually.
* Educate patients and caregivers about the risks of suicidal behavior, severe rash, and CNS depression.
***
*Disclaimer: This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines before making any treatment decisions. Dosing may vary based on individual patient factors and local protocols.*
